-
Benchmark Initiates Coverage On Exact Sciences Corporation At Buy, $9 PT
Thursday, April 28, 2011 - 8:56am | 195Benchmark is initiating coverage of Exact Sciences Corporation (NASDAQ: EXAS) with a Buy rating and $9 price target. Exact is developing the Cologuard stool-based DNA test with the intention of being the first non-invasive screening diagnostic that can prevent colorectal cancer by detecting...
-
Celgene Reports EPS of $0.83 vs. $0.80 Estimate; Revenues $1.13B vs. $1.08B Estimate (CELG)
Thursday, April 28, 2011 - 8:37am | 21Celgene (NASDAQ: CELG) Reports EPS of $0.83 vs. $0.80 Estimate; Revenues $1.13B vs. $1.08B Estimate
-
CytRx's INNO-206 Receives FDA Approval for Orphan Drug (CYTR)
Thursday, April 28, 2011 - 8:32am | 68CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that its tumor-targeting pro-drug candidate INNO-206 has been approved for orphan drug designation for the treatment of patients with pancreatic cancer by the Office of Orphan Products...
-
Brean Murray Raises REGN Target From $67 To $78
Thursday, April 28, 2011 - 8:27am | 29Brean Murray is raising its PT on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) from $67 from $78. Regeneron Pharmaceuticals closed Wednesday at $67.05.
-
Oppenheimer Comments On Idenix Pharmaceuticals 1Q11 Results
Thursday, April 28, 2011 - 8:19am | 147In a report published by Oppenheimer, Idenix Pharmaceuticals (NASDAQ: IDIX) IDIX reported 1Q11 results. Oppenheimer said that the company remains on track to initiate a 12-week ph.IIb study evaluating IDX184 with PEG/RBV in 2H11. “Based on ph.IIa results, we see a good probability '184 will...
-
Benzinga's Top Pre-Market NASDAQ Losers (AKAM, FLEX, MLNX, ITMN)
Thursday, April 28, 2011 - 8:19am | 118Akamai Technologies Inc (NASDAQ: AKAM) dipped 12.35% to $35.92 in the pre-market session. AKAM issued downbeat Q2 projections. Flextronics International Ltd (NASDAQ: FLEX) lost 7.46% to $6.95 in the pre-market session. FLEX reported weaker-than-expected Q4 results. Mellanox Technologies Ltd (...
-
Benzinga's Top Downgrades (ITRI, OTEX, MBLX, AOB)
Thursday, April 28, 2011 - 8:19am | 134Itron Inc (NASDAQ: ITRI) was downgraded by Wunderlich from "hold" to "sell." ITRI's shares closed at $55.18 yesterday. Itron's trailing-twelve-month ROE is 7.41%. Benchmark Company downgraded Open Text Corporation (NASDAQ: OTEX) from “hold” to “sell.” OTEX's stock closed at $64.18 yesterday. Open...
-
Brean Murray Reiterates Buy Rating On NPSP
Thursday, April 28, 2011 - 8:10am | 62Brean Murray is reiterating its Buy rating on shares of NPS Pharmaceuticals, Inc. (NASDAQ: NPSP). “Although there are no additional presentations directly related to Gattex during the 2011 DDW conference, we draw investor attention to several abstracts related to other GLP-2 analog, such as FE...
-
NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid (NGSX)
Thursday, April 28, 2011 - 8:08am | 81NeurogesX (Nasdaq: NGSX) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent entitled, "Methods and Compositions for Administration of TRPV1 Agonists." The allowed claims include method of use, formulation and system claims. The...
-
Affymax and Takeda Report Additional Phase 3 Clinical Trial (AFFY)
Thursday, April 28, 2011 - 8:06am | 134Affymax (Nasdaq: AFFY) and Takeda Pharmaceutical Company Limited , today announced results of additional analyses from two Phase 3 studies of the investigational agent, peginesatide in chronic renal failure patients on dialysis with anemia. Building on the primary analysis of the EMERALD studies,...
-
UPDATE: Piper Jaffray Downgrades Metabolix to Underweight (MBLX)
Thursday, April 28, 2011 - 7:52am | 150Piper Jaffray is out with its report today on Metabolix (NASDAQ: MBLX), downgrading MBLX from Neutral to Underweight. In a note to clients, Piper Jaffray writes, "We are lowering our rating on shares of MBLX to Underweight and taking our price target to $7 following a 1Q11 print that was in-line...
-
United Therapeutics Reports EPS of $1.29 vs. $0.64 Estimate; Revenues $165.5M vs. $178.02M Estimate (UTHR)
Thursday, April 28, 2011 - 7:37am | 22United Therapeutics (NASDAQ: UTHR) Reports EPS of $1.29 vs. $0.64 Estimate; Revenues $165.5M vs. $178.02M Estimate
-
United Therapeutics (NASDAQ: UTHR) Reports EPS of $1.29 vs. $0.64 Estimate; Revenues $165.6M vs. $178.02M Estimate
Thursday, April 28, 2011 - 7:20am | 22United Therapeutics (NASDAQ: UTHR) Reports EPS of $1.29 vs. $0.64 Estimate; Revenues $165.6M vs. $178.02M Estimate
-
Piper Jaffray Downgrades Metabolix To Underweight, PT To $7
Thursday, April 28, 2011 - 6:29am | 27Piper Jaffray has downgraded Metabolix (NASDAQ: MBLX) from Neutral to Underweight and has lowered the price target from $9 to $7.
-
Daytrading Stocks to Watch for 04/28- SSN, HDY, DRYS, ARNA, IRE, CYCC, SOMX, REDF, AIB, YRCW, SHZ, LLNW, LVLT, JSDA
Thursday, April 28, 2011 - 6:07am | 1534Samson Oil & Gas Limited (AMEX:SSN)- Samson Oil & Gas Limited announced the issuance of 492,400 ordinary fully paid shares at AUD 0.015 per share. The shares were issued pursuant the exercise of listed options. Hyperdynamics Corporation (AMEX:HDY)- Hyperdynamics Corporation, incorporated...